Robert Cavorsi
Corporate Officer/Principal bei ORGANOGENESIS HOLDINGS INC.
Vermögen: 157 944 $ am 31.05.2024
Aktive Positionen von Robert Cavorsi
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ORGANOGENESIS HOLDINGS INC. | Corporate Officer/Principal | 01.01.2021 | - |
Karriereverlauf von Robert Cavorsi
Ehemalige bekannte Positionen von Robert Cavorsi
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Vertrieb & Marketing | 01.01.2015 | 01.01.2016 |
Ausbildung von Robert Cavorsi
| The Pennsylvania State University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
Operativ
| Corporate Officer/Principal | 1 |
| Sales & Marketing | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ORGANOGENESIS HOLDINGS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Health Technology |
- Börse
- Insiders
- Robert Cavorsi
- Erfahrung
